All 1 tracked stories fall under one category: pharma. Kyndryl Holdings, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ClaimsFiler
All 1 tracked stories fall under one category: pharma. Kyndryl Holdings, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Biotech story that mention ClaimsFiler, all published on February 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ClaimsFiler. Shared-story counts are live from our verified record — not editorial picks.
Investors in uniQure N.V. and Kyndryl Holdings have until April 13, 2026, to file as lead plaintiffs in securities class action lawsuits following significant stock losses. The litigation highlights increasing regulatory and disclosure pressures on biotech firms specializing in complex gene therapies.
ClaimsFiler is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.